1. Introduction {#s0005}
===============

Methamphetamine dependence and HIV infection have been termed a "double epidemic" ([@bb0200]). A decade ago, populations at risk for HIV or infected with HIV used methamphetamine at a rate approximately 10 times higher than the general population ([@bb0115]). While current estimates show a decline in both methamphetamine use ([@bb0365]) and new HIV infections ([@bb0225]), the joint occurrence is still a concern due to the reduced effectiveness of antiretroviral therapy among HIV infected people who are actively using methamphetamine ([@bb0155]). In addition, methamphetamine consumption is associated with increased engagement in high-risk sexual behaviors, which can lead to the acquisition of HIV and other sexually transmitted infections. This relationship between methamphetamine use and sexual risk behavior has been found across genders and sexual orientations ([@bb0115]; [@bb0230]).

The effects of concurrent HIV infection and methamphetamine dependence on brain morphometry and function could be hypothesized to relate in several ways: they could be additive (non-interactive), or multiplicative (interactive). An interactive effect could be adversely synergistic, meaning that the effects exacerbate one another (e.g., leading to a greater reduction in brain volume) or antagonistic, meaning that one effect counters the other. Evidence for a purely additive, non-interactive effect of HIV and methamphetamine dependence has been found at different levels of analysis, including such outcomes as brain metabolites (Chang, Ernst, Speck, & Grob, 2005), cerebral blood flow (Ances, Vaida, Cherner, & Yeh, 2011), and neuropsychological functioning ([@bb0070]; [@bb0405]; Scott, Woods, Matt, & Meyer, 2007).

Mechanistically, however, an adversely synergistic effect is also plausible. Methamphetamine dependence may potentiate the neurotoxic effects of the HIV pathogen via a variety of mechanisms, including alterations to the blood-brain-barrier ([@bb0065]; [@bb0285]; [@bb0305]; [@bb0320]; [@bb0400]; Turchan, Anderson, & Hauser, 2001). However, (to our knowledge) the only existing morphometric study reported opposing influence of the two variables on volume in both distinct and overlapping brain regions ([@bb0250]). Specifically, HIV was associated with reduced frontal, temporal, limbic and striatal volume, whereas methamphetamine dependence was associated with increased volume in the basal ganglia and parietal cortex ([@bb0250]).

1.1. Independent Effects of HIV {#s0010}
-------------------------------

HIV infection and methamphetamine dependence have each been associated with changes in brain morphometry, although results have been inconsistent. In some studies, HIV infection has been associated with reduced cortical volume ([@bb0460]; [@bb0035]) or with regional cortical thinning ([@bb0150]; [@bb0450]; [@bb0430]; [@bb0420]; [@bb0480]). Other studies have found no difference in either cortical volume or thickness associated with HIV infection ([@bb0110]; [@bb0425]; [@bb0120]; [@bb0440]). A recent meta-analysis found that total gray matter volume was significantly smaller among HIV infected individuals than among non-infected controls, although the standardized mean difference was small (−0.28; [@bb0375]). Factors that may explain the inconsistency across studies include viral load at the time of the study ([@bb0260]; [@bb0150]; [@bb0480]), retroviral treatment status ([@bb0125]; [@bb0155]), and age of the sample ([@bb0020]; [@bb0250]).

1.2. Independent effects of methamphetamine dependence {#s0015}
------------------------------------------------------

Methamphetamine users have been reported to have smaller cortical volumes compared with non-using control participants, however the lobes involved vary from study to study ([@bb0050]; [@bb0135]; [@bb0205]; [@bb0270]; [@bb0315]; [@bb0325]; [@bb0360]; [@bb0475]). Larger volumes have also been reported to be associated with methamphetamine use in the parietal and right superior frontal cortex ([@bb0250]; [@bb0275])-- the latter finding was observed only among males. Despite these findings of regional volume changes associated with methamphetamine use, a study of cortical thickness among amphetamine users found no regional differences between healthy controls and non-alcohol consuming amphetamine users ([@bb0290]). Factors that likely contribute to the variability across studies include gender ([@bb0275]), age at first use ([@bb0250]; [@bb0325]), total amount of drug exposure and potency ([@bb0270]; [@bb0315]; [@bb0360]), current use vs. abstinence ([@bb0075]; [@bb0265]), and current age ([@bb0360]).

1.3. Cortical volume, thickness and area considered separately {#s0020}
--------------------------------------------------------------

As evident from this brief review, there is conflicting evidence about the presence, direction and localization of brain changes associated with HIV and methamphetamine dependence. In addition to the demographic and disorder-specific variables described above, previous inconsistencies may be partially due to heterogeneity in morphometric outcome variables. Early investigations of brain structure used available methods to estimate cortical volume, which captures both thickness and folding in a given area ([@bb0250]). Advances in segmentation software ([@bb0130]; [@bb0170]; [@bb0175]) now permit researchers to distinguish cortical thickness and surface area from their product---cortical volume---which tends to correlate more strongly with surface area than with thickness ([@bb0500]). Cortical thickness and surface area show different patterns of change with age ([@bb0295]), and twin studies have revealed distinct genetic contributions to each, supporting the importance of considering them as separate outcome measures in studies of brain morphometry ([@bb0255]; [@bb0385]; [@bb0500]).

1.4. Current approach {#s0025}
---------------------

Using current segmentation techniques, we examined cortical thickness, area and volume separately in a cross-sectional sample of individuals who varied in HIV status and methamphetamine dependence. In our first aim, we investigated quantitative brain differences in 137 participants across four groups in a 2 × 2 design: HIV seropositive and methamphetamine-dependent participants (HIV+/METH+), HIV seropositive with no methamphetamine dependence (HIV+/METH-), HIV seronegative with methamphetamine dependence (HIV-/METH+) and HIV seronegative with no methamphetamine dependence (HIV-/METH-). We also investigated the impact of disorder-specific variables on cortical morphometry. Given the inconsistent findings in the literature, we tested non-directional hypotheses in regions of interest (ROIs) that parcellated the cortex. This whole-cortex, ROI approach was taken with the goal of clarifying discrepant results in the literature by examining effects of HIV infection and methamphetamine dependence and their interaction on cortical volume and its separate component parts---thickness and area.

The second aim was to investigate separately the interactive effects of HIV infection with age and methamphetamine dependence with age on thickness, area and volume. HIV patients are living longer than a decade ago and individuals who began using methamphetamine in the United States during the 1980s and 1990s are also aging ([@bb0245]; [@bb0340]). Thus, in addition to investigating the possible additive, adversely synergistic, or antagonistic effects of HIV infection and methamphetamine use, it is clinically important to also examine how the effects of these disorders on brain morphometry may differ by age. Findings in the literature have been mixed, supporting HIV-related accelerated ([@bb0390]), premature ([@bb0090]; [@bb0470]), or parallel aging ([@bb0110]), and methamphetamine-related accelerated aging ([@bb0360]). To examine possible aging effects in our sample, we investigated the interactions of HIV diagnosis or methamphetamine dependence with age. We also looked for interactions between our clinical variables of interest and participant age; we acknowledge, however, that our cross-sectional design limits the conclusions we can draw about age-related trajectories.

2. Methods {#s0030}
==========

2.1. Participants {#s0035}
-----------------

One hundred and thirty-seven individuals were recruited into a 2 (HIV seropositive vs. seronegative) by 2 (METH dependent vs. non-dependent) design at the University of California, San Diego Translational Methamphetamine AIDS Research Center (TMARC). Sixty-nine HIV seropositive participants were recruited from HIV treatment centers and community organizations in San Diego County. Thirty-one of the seropositive participants were also methamphetamine dependent (HIV+/METH+). Twenty-eight individuals who were methamphetamine dependent but HIV seronegative (HIV-/METH+) were recruited from substance abuse outreach and rehabilitation programs in San Diego County. Forty individuals seronegative for HIV who were also not methamphetamine dependent were recruited from community advertisements and word-of-mouth from the same communities as the patient groups (HIV-/METH-). Groups were not explicitly matched on demographic variables at the time of recruitment nor were demographic characteristics used to select individuals for imaging. Thus, any group differences on demographic variables found in the analysis likely reflected population differences among the groups within the communities from which they were recruited. Although recruitment was not stratified by age, participants were classified as less than or equal to 50 years of age or greater when recruited.

Potential participants met general inclusion criteria if they were at least 18 years old, had the capacity to provide informed consent, and spoke and understood English sufficiently to take validly a battery of neuropsychological tests and to complete self-report scales. Individuals were excluded from the study if they had histories of medical, neurological or severe psychiatric conditions unrelated to HIV disease or to methamphetamine use. These exclusionary conditions included seizure disorders, closed head injuries with loss of consciousness \>30 min, central nervous system neoplasms, opportunistic infections, Hepatitis C and schizophrenia. Additionally, participants were excluded from the study if they met criteria for alcohol dependence in the past year, drug abuse (including cocaine) in the past year or drug dependence in the past five years (with the exception of methamphetamine dependence in the methamphetamine group). Given its prevalence in our populations, participants with histories of marijuana abuse or dependence were included. Participants were excluded if they had Wide Range Achievement Test (WRAT) Reading Scale Score \< 80, a history of learning disability, or were ineligible for magnetic resonance scans (e.g., metal contraindication, claustrophobia).

HIV status was determined by the Med Mira Rapid HIV antibody test. Among HIV+ participants, CD4+ T cell counts were measured by flow cytometry at a Clinical Laboratory Improvement Amendments-certified medical center laboratory. HIV RNA levels were measured in plasma by reverse transcriptase PCR (Roche Amplicor, v. 1.5, lower limit of quantification 50 copies/mL). For each individual testing HIV positive, a consensus case conference met to determine if the Frascati criteria for HIV-associated neurocognitive disorder (HAND) were met ([@bb0030]). CD4 nadir was obtained by self-report, with confirmation by documented prior measurements in a subset of individuals. Date of nadir was also obtained by self-report, as was estimated duration of HIV diagnosis.

We interviewed potential participants for substance use in order to determine whether they met the criteria for methamphetamine dependence as defined in the *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition* (DSM-IV; [@bb0015]). The interview provided information about age of first methamphetamine use, days since last use, lifetime quantity used, total days used, use density (lifetime grams per day of use), intravenous drug use, drug treatment history and other categories of drug use ([@bb0060]).

The study was approved by the University of California, San Diego Institutional Review Board and informed consent was obtained from each participant prior to enrollment.

2.2. Imaging {#s0040}
------------

T1-weighted structural images were obtained on a 3.0 T General Electric MR750 scanner with GE DV25 Software. Image acquisition used an Array Spatial Sensitivity Encoding Technique (ASSET) for parallel and accelerated imaging with an 8-channel head coil and acquired as an Inversion Recovery-Spoiled Gradient Recalled (IR-SPGR) echo sequence (TE = 3.2 ms, TR = 8.2 ms, TI = 450 ms, flip angle = 12°, NEX = 1, matrix = 256 × 256, FOV = 24 cm, in-plane resolution = 0.9375 mm × 0.9375 mm, slice thickness = 1.2 mm, 172 slices). Using Freesurfer v5.3.0, we removed extracranial signal; segregated gray matter, white matter, and cerebrospinal fluid compartments; corrected the B1 field bias; and reconstructed the cortical surface ([@bb0130]; [@bb0170]; [@bb0180]). The results of the cortical surface reconstruction were visually inspected and manually edited as needed. We next used Freesurfer to label each gyral region of interest (ROI) on the cortex using the Desikan-Killiany atlas ([@bb0145]). Mean cortical area, volume and thickness were estimated for each ROI ([@bb0175]; [@bb0185]). Global measures for each of these three morphometric values were computed by averaging over all 68 ROIs across the two hemispheres. Global cortical volume and area were strongly correlated (*r* = 0.86, *p* \< .001) in our sample, whereas volume and thickness were less strongly related (*r* = 0.55, p \< .001). Global area and thickness were not significantly correlated (*r* = 0.10, *p* = .14). An estimate of intracranial volume was obtained from the Freesurfer processing (based on [@bb0055]). Participants were not scanned if they tested positive for methamphetamine or other drugs (excluding marijuana) on the day of the scan. Participants reported abstaining from marijuana the day they were imaged.

2.3. Statistical Analysis prior to analyzing group differences in regional cortical thickness, area or volume, we used {#s0045}
----------------------------------------------------------------------------------------------------------------------

Linear regression to investigate in the entire sample the association between potential covariates found in the literature to be related to these three cortical measurements. The regression model -- using age, gender, and intracranial volume as predictors -- revealed significant associations between age and global cortical area, volume and thickness, a significant association between intracranial volume and cortical area and volume but not thickness, and no significant association between gender and any of the three cortical values. In the analyses below, age was used as a covariate in the ANCOVAs involving area, volume or thickness, whereas intracranial volume was combined with age as covariates in the analysis of cortical area and cortical volume.

For each ROI, we performed a 2 × 2 analysis of covariance (ANCOVA) to investigate the association between HIV status (seropositive/seronegative), methamphetamine dependence (dependent/not) and their interaction with cortical area, volume and thickness. We calculated partial eta-squared (*η*~*p*~^2^: small = 0.01; medium = 0.06; large = 0.14, based on definitions in [@bb0100], pp. 284--288) to estimate standardized effect sizes. To investigate the relationship between cortical thickness (area, volume), age and the age interactions with HIV status, we regressed cortical thickness onto HIV status (effects coded), age (mean centered), and their multiplicative interaction. We performed a similar analysis involving age and methamphetamine dependence. For these analyses, we used the False Discovery Rate to adjust for multiple statistical tests across ROIs ([@bb0045]) with q = 0.10. Given 34 ROIs and our total sample size, for any member of a set of trending *p*-values (single test *p* \< .05) to be considered significant after correction for multiple statistical tests, at least one member of the set needed to have an η^2^ \> 0.065, a medium effect size.

In exploratory analyses, we examined the associations of each of the three cortical measurements with disorder-related variables (HIV: viral load at the time of the study, CD4 nadir, and duration of infection; Methamphetamine: age at first use, total amount of drug exposure, duration of use, and log transformed density of use.)

To explore further possible multiplicative effects on brain variables of HIV infection with methamphetamine dependence, we performed regression analyses involving interactions of HIV diagnosis with the methamphetamine disorder-related variables and interactions of methamphetamine diagnosis with HIV disorder-related variables. For example, among individuals with HIV diagnoses (HIV+/METH- and HIV+/METH+), we regressed global cortical area onto methamphetamine dependence (HIV+/METH- vs. HIV+/METH+, effects coded), CD4 nadir (mean centered) and the multiplicative interaction of methamphetamine dependence with CD4 nadir. Similar analyses were performed among individuals with methamphetamine dependence. When performing these regression analyses, we were primarily interested in testing potential interaction effects. So, only the results of these interactions are reported below.

3. Results {#s0050}
==========

3.1. Demographic and disorder related variables {#s0055}
-----------------------------------------------

The study groups did not differ significantly on gender or handedness ([Table 1](#t0005){ref-type="table"}). There was no main effect of HIV diagnosis or a main effect of methamphetamine dependence or their interaction on age. Although there was no significant main effect of HIV diagnosis or the interaction of HIV diagnosis with METH dependence on education, methamphetamine-dependent participants (HIV-/METH+ and HIV+/METH+) had significantly less education than non-dependent participants, *F*(1, 129) = 10.575, *p* = .001, *η*~*p*~^2^ = 0.08. Although there was no main effect of HIV diagnosis or methamphetamine dependence on WRAT reading (HIV: *p* = .841, *η*~*p*~^2^ \< 0.001; METH: *p* = .100, *η*~*p*~^2^ = 0.021), the interaction of HIV with METH was significant for WRAT reading, *F*(1, 129) = 4.929, *p* = .028, *η*~*p*~^2^ = 0.04, due to the low score of the METH dependent group among HIV seronegative participants.Table 1Demographic characteristics of participants.Table 1GroupNAgeEducationWRAT Reading%Male%Right HandedControl\
*HIV-/METH-*4040.35 (12.62)14.25\
(2.10)106.98\
(13.55)85.0085.00HIV only\
*HIV+/METH-*\
38\
44.79\
(14.02)\
14.49\
(2.50)\
102.16\
(11.30)\
92.10\
84.21METH only\
*HIV-/METH+*\
28\
39.93 (10.34)\
12.41\
(2.37)\
98.00\
(11.97)\
89.28\
89.28Dual\
*HIV+/METH+*\
31\
41.00\
(8.23)\
13.89\
(2.04)\
103.26\
(13.64)\
100.00\
83.87[^1]

The HIV+/METH- and HIV+/METH+ groups did not significantly differ on current CD4 count (*η*~*p*~^2^ \< 0.01), reported CD4 nadir (*η*~*p*~^2^ = 0.02), or estimated duration of infection (*η*~*p*~^2^ = 0.01).

Moreover, the HIV+/METH- and HIV+/HIV+ groups were not significantly different in percentage with AIDS, HAND, or detectable plasma HIV RNA, or on ART ([Table 2](#t0010){ref-type="table"}A). The HIV-/METH+ and HIV+/METH+ groups did not differ significantly on age methamphetamine was first used (*η*~*p*~^2^ \< 0.01), total days used (*η*~*p*~^2^ \< 0.01), total amount of methamphetamine used (*η*~*p*~^2^ = 0.01), log10 density of use, (*η*~*p*~^2^ \< 0.01), or days since last use (*η*~*p*~^2^ = 0.04). Similarly, the HIV-/METH+ and HIV+/METH+ groups did not differ on the percentage having been treated for methamphetamine dependence nor on history of intravenous drug use.Table 2Clinical Characteristics of Patient Groups.Table 2Clinical VariableHIV InfectionMethamphetamine DependenceDualA.**HIV Variables**Duration of HIV Infection (Years)\
9.77 (9.21)\
8.10 (7.11)\
\
AIDS (Y/N)\
\
51.4%\
\
37.5%\
\
Current CD4\
\
520.47 (257.84)\
\
562.34 (240.25)\
\
CD4 Nadir\
\
247.56 (180.79)\
\
296.67 (185.24)\
Combination ART[1](#tf0005){ref-type="table-fn"}\
83.8%\
93.8%\
Undetectable Plasma RNA\
62.2%\
56.7%\
HAND[2](#tf0010){ref-type="table-fn"}\
45.9%\
53.1%  \
B.**Methamphetamine Variables**\
Age at First Use (Years)\
24.52 (10.04)\
25.07 (8.82)\
\
Days Since Last Use\
\
119.23 (145.52)\
\
183.21 (168.05)\
Total Lifetime Days Used\
\
2317.44 (1513.51)\
\
2338.24 (2513.84)\
Log~10~ (Total Lifetime Quantity)\
\
3.12 (0.66)\
\
2.93 (0.85)\
Use Density\
1.16 (1.17)\
1.34 (1.77)\
Intravenous Drug Use (Y/N)\
50.0%\
41.94%\
Methamphetamine Treatment -- Ever (Y/N)\
80.8%\
78.6%[^2][^3]

3.2. Imaging results {#s0060}
--------------------

The literature does not provide clear support for a lateralized effect of HIV infection or methamphetamine dependence on brain volume, area, or thickness. Moreover, when we examined each ROI for interactions of brain laterality with HIV infection or methamphetamine dependence, none of the few significant single-test results observed across the three study variables survived multiple statistical test correction. Therefore, the results reported below are averaged across hemisphere for each ROI.

### 3.2.1. Main effect of HIV Diagnosis {#s0065}

There were six ROIs where cortical area was trending smaller in the HIV seropositive group than in the seronegative group (rostral middle frontal gyrus, *η*~*p*~^2^ = 0.03; caudal anterior cingulate, *η*~*p*~^2^ = 0.04; fusiform gyrus, *η*~*p*~^2^ = 0.04; inferior parietal lobe, *η*~*p*~^2^ = 0.04; superior parietal lobe, *η*~*p*~^2^ = 0.05 temporal pole, *η*~*p*~^2^ = 0.06). However, the effect sizes were only small to medium, and none survived correction for multiple statistical tests. Five regions for which cortical area trended smaller among HIV infected participants also trended towards smaller cortical volumes (rostral middle frontal gyrus, *η*~*p*~^2^ = 0.06; fusiform gyrus, *η*~*p*~^2^ = 0.04; inferior parietal lobe, *η*~*p*~^2^ = 0.08; superior parietal lobe, *η*~*p*~^2^ = 0.07, temporal pole, *η*~*p*~^2^ = 0.04). Additionally, cortical volumes trended smaller in the postcentral gyrus, *η*~*p*~^2^ = 0.04 and in the precuneus, *η*~*p*~^2^ = 0.04. The differences in cortical volumes remained significant following correction for multiple statistical tests in the rostral middle frontal gyrus and in the inferior and superior parietal lobes. Cortical thickness in the HIV seropositive and seronegative groups did not significantly differ for any ROI (all *η*~*p*~^2^ \< 0.03).

Among HIV seropositive participants, smaller global cortical area and volume were associated with lower CD4 nadir (area *r* = 0.35, *p* = .004; volume, *r* = 0.29, *p* = .02). Longer duration of infection was significantly associated with smaller global cortical volume (*r* = −0.33, *p* = .008). None of the HIV variables was significantly correlated with global cortical thickness.

### 3.2.2. Main effect of Methamphetamine Dependence {#s0070}

Cortical area did not differ between the methamphetamine-dependent and nondependent groups in any ROI (all *η*~*p*~^2^ \< 0.03). There was a trend for cortical volume to be smaller in the inferior parietal lobe (*η*~*p*~^2^ = 0.04) and in the posterior cingulate gyrus (*η*~*p*~^2^ = .03). However, the effect sizes were modest and did not survive multiple test correction. Cortical thickness trended smaller in the methamphetamine-dependent group in posterior cingulate (*η*~*p*~^2^ = 0.07), middle temporal (*η*~*p*~^2^ = 0.05), and inferior parietal lobe (*η*~*p*~^2^ = 0.05), precuneus (*η*~*p*~^2^ = 0.05), and caudal middle frontal (*η*~*p*~^2^ = 0.03) and superior parietal cortex (*η*~*p*~^2^ = 0.03). However, only the finding in the posterior cingulate gyrus remained significant after adjustment for multiple statistical tests. We continued to observe a significant effect of methamphetamine dependence on posterior cingulate thickness when the difference in education between the methamphetamine-dependent and non-dependent groups was statistically controlled.

Among methamphetamine-dependent participants (HIV+/METH+ and HIV-/METH+), individuals who were older at their first use of methamphetamine had thinner cortex globally, *r* = −0.29, *p* = .029. Thickness was not significantly related to duration of drug use, total drug use or recency of drug use. Global cortical area was negatively related to total days used, *r* = −0.29, *p* = .030, but was not significantly associated with age at first use, total drug used, and time since last use. The association of smaller global cortical area with more total days used remained significant after intracranial volume was added to the regression model. Global cortical volume was not significantly correlated with any methamphetamine use variable.

### 3.2.3. Interaction of HIV and Methamphetamine {#s0075}

In no ROI was the interaction of HIV infection with methamphetamine dependence significant for cortical thickness measures (all *η*~*p*~^2^ \< 0.03). There were six ROIs where the interaction of HIV diagnosis with methamphetamine dependence trended significant (*p* \< .05, uncorrected) for cortical area (caudal anterior cingulate, *η*~*p*~^2^ = 0.03; caudal middle frontal cortex, *η*~*p*~^2^ = 0.03; cuneus, *η*~*p*~^2^ = 0.05; isthmus of the cingulate gyrus, *η*~*p*~^2^ = 0.04; lateral orbital frontal cortex, *η*~*p*~^2^ = 0.03; precentral gyrus, *η*~*p*~^2^ = 0.05), although none of these effects were large enough to survive multiple statistical test correction. Nonetheless, the pattern of the interactive effect of HIV diagnosis with methamphetamine dependence on cortical area was consistent across all of the ROIs. In the HIV seronegative groups, mean cortical area was smaller among methamphetamine-dependent participants, whereas in the HIV seropositive groups, mean cortical area was larger among methamphetamine-dependent participants. We observed trends for this same interactive pattern involving cortical volume in the precentral (*η*~*p*~^2^ = 0.04) and paracentral (*η*~*p*~^2^ = 0.03) gyri.

Among individuals with methamphetamine dependence, the presence or absence of HIV infection did not significantly interact with age at first methamphetamine use, days since last use, total days of use, total quantity used or density of use when predicting cortical thickness, area or volume. Moreover, among individuals with HIV infection, the presence or absence of methamphetamine dependence did not interact with current CD4 level, CD4 nadir, or duration of HIV infection when predicting cortical thickness, area, or volume.

3.3. Interactions with Age {#s0080}
--------------------------

In no ROI was cortical area or volume significantly related to the interaction of age with HIV status. For cortical thickness, trend interactions of HIV status with age were found in 11 brain regions, although only eight of the ROIs survived multiple statistical test correction (caudal middle frontal cortex, fusiform gyrus, inferior parietal cortex, superior parietal cortex, superior temporal sulcus area, supramarginal gyrus, middle temporal gyrus, precuneus). [Fig. 1](#f0005){ref-type="fig"} presents a brain map of the standardized regression weights for regions where a significant interaction of HIV status with age was observed for cortical thickness. The largest interaction effects were in posterior brain regions.Fig. 1Standardized beta maps of Freesurfer regions with significant HIV by Age interaction effects on cortical thickness (multiple statistical test correction).Fig. 1

In the eight ROIs with a significant interaction of age with HIV diagnosis, the pattern of the interaction was the same. To summarize the interaction pattern, we averaged over cortical.

thickness associated with the eight ROIs. Not surprisingly, this linear regression model was also significant, *F*(3,133) = 18.705, *p* \< .001, with HIV status significantly interacting with age: *β* = 0.281, *p* \< 001 ([Fig. 2](#f0010){ref-type="fig"}). Moreover, although age and duration of HIV infection based on patient report were correlated, *r* = 0.54, *p* \< .001, duration of HIV seropositive status was not significantly related to cortical thickness in regions where HIV interacted with age *r*^*2*^ = 0.048, *p* = .078. As shown in [Fig. 2](#f0010){ref-type="fig"}, age is associated with a more gradual slope among HIV seropositive individuals than among HIV seronegative individuals. Moreover, the Y-intercept for the HIV seropositive group was less than in the HIV seronegative group with no overlap in the 95%. confidence intervals (HIV seropositive intercept = 2.427 mm \[95% CI: 2.339 to 2.512\]; HIV seronegative intercept = 2.667 mm \[95% CI: 2.590 to 2.743\]). As seen in [Fig. 2](#f0010){ref-type="fig"}A, individuals with HIV infection who are in their early 20s have, on the average, global cortical thickness values similar to typical seronegative individuals in their early 40s. When we restricted the regression analysis to the 78 participants without methamphetamine dependence, the model remained significant, *F*(3, 74) = 13.988, *p* \< .001, with HIV status significantly interacting with age (*β* = 0.267, *p* = 005), and showed the same pattern of results as in the full sample ([Fig. 2](#f0010){ref-type="fig"}B).Fig. 2Effect of the interaction of age and HIV status on global cortical thickness (mm). (A) All participants (*N* = 137). (B) Participants without methamphetamine dependence (*N* = 78).Fig. 2

In no ROI was cortical area, volume or thickness related to the interaction of methamphetamine dependence with age after correction for multiple statistical tests. There was a trend, however, for the methamphetamine-dependent groups to be associated with smaller area of the isthmus of the cingulate gyrus with increasing age compared with the methamphetamine negative groups (*p* = .04).

4. Discussion {#s0085}
=============

4.1. Effects of HIV and methamphetamine dependence {#s0090}
--------------------------------------------------

We observed a trend for HIV positive individuals to have smaller cortical area in six regions of interest, although these effects were small and did not survive multiple statistical test correction. In three of these six regions (rostral middle frontal gyrus and the inferior and superior parietal lobes), we observed smaller cortical volumes at a medium effect size, which were significant after multiple-test correction. Associations between HIV status and cortical thickness were small and non-significant in all brain areas. A recent meta-analysis found significant effects of HIV status on brain volumes, with smaller effects appearing in more recently published papers ([@bb0375]). The authors attributed the trend of diminishing effect sizes to the increased use of combined antiretroviral treatment among HIV infected patients. In our sample, 88.3% of individuals with HIV infection were on cART with average CD4 counts within the normal range. Even with this high treatment rate, we found associations between HIV clinical variables and structural brain measurements. In particular, CD4 nadir was positively associated with both global cortical area and volume, whereas duration of HIV infection was associated with smaller global cortical volume. Other groups have similarly reported that the severity of the initial immune compromise in HIV has long-term effects on brain area and volume, even when patients are adequately treated ([@bb0195]; [@bb0240]; [@bb0420]).

We found only small and statistically non-significant effects of methamphetamine dependence on regional cortical area and only small trends towards reduced cortical volume in the inferior parietal lobe and in the posterior cingulate cortex. Methamphetamine dependence trended towards an association with smaller cortical thickness in some frontal and temporal regions and in the inferior parietal lobe and posterior cingulate gyrus, with the effect in the posterior cingulate gyrus surviving multiple statistical test correction. Because we found, as have others, that cortical volume is more strongly related to cortical area than cortical thickness ([@bb0500]), our finding that methamphetamine dependence was associated with thickness rather than area suggests that methamphetamine\'s impact on brain morphometry might be too subtle for cortical volume measures to detect reliably -- except in more chronically exposed samples where total days of use has sufficiently accumulated to affect cortical area. The subtlety of the methamphetamine effect and variation in accumulated methamphetamine use across studies likely contribute to the inconsistent brain volume findings reported in the methamphetamine literature.

4.2. No interaction between HIV status and methamphetamine dependence {#s0095}
---------------------------------------------------------------------

All trends for an interactive effect of HIV status and methamphetamine dependence on regional cortical volume, area, or thickness were small and did not survive correction for multiple statistical tests. Moreover, the diagnosis of methamphetamine dependence did not interact with any HIV disease variables, nor did HIV status interact with methamphetamine variables. The small effect sizes of the interaction of HIV diagnosis with methamphetamine dependence agrees with previous findings for brain metabolites ([@bb0075], [@bb0080]) and cerebral blood flow ([@bb0025]). We did find six regions where an interaction of HIV infection with methamphetamine dependence was significant for cortical area prior to correction for multiple statistical tests. In all six areas, the pattern of the effect was inconsistent with the hypothesis that methamphetamine dependence would exacerbate the adverse effect of HIV infection on the brain. Rather, the pattern was compatible with an antagonistic effect -- mean area was smaller in the methamphetamine positive group than in the methamphetamine negative group when participants were seronegative for HIV, but larger in the methamphetamine positive group when participants were seropositive for HIV. There were trends towards this same interactive pattern for cortical volume in precentral and paracentral gyri.

In previous work, investigators have speculated that volumetric increases associated with methamphetamine use are due to enhanced neuroplasticity or neuroinflammation ([@bb0075]; [@bb0250]). That increased cortical area was associated with methamphetamine dependence only among HIV infected individuals, if replicated, would support the neuroinflammatory hypothesis. Factors that could contribute to enhanced neuroinflammation in individuals positive for both HIV infection and methamphetamine use include reduced effectiveness of antiretrovirals, initiation of methamphetamine use after seroconversion, and reduced adherence to antiretroviral treatment ([@bb0155]; [@bb0345]; [@bb0350]). Several neuropathological mechanisms associated with neuroinflammation that could increase cortical area or volume include astrocytic hypertrophy, cytotoxic edema, and vasogenic edema caused by a breakdown of the blood-brain barrier ([@bb0215]; [@bb0190]). The possibility that cytotoxic edema, in particular, might occur during HIV-related neuroinflammation is supported by the finding that the aquaporin AQP4, which contributes to cytoplasmic edema, is significantly elevated in brain homogenates of non-demented HIV-infected individuals ([@bb0040]; [@bb0455]). The hypothesis that aquaporins contribute to volumetric and area changes in HIV and methamphetamine merits further exploration.

4.3. Interactions with age {#s0100}
--------------------------

### 4.3.1. Methamphetamine dependence {#s0105}

There were no trend interactions of methamphetamine by age for cortical thickness, area, or volume that survived multiple statistical test correction. Our negative finding differs from the steeper age-related slope in methamphetamine users compared with non-users reported for cortical volume by [@bb0360]. However, the average number of days of methamphetamine use in our study (\~77 months) was considerably less than in the Nakama study (120 months). Given that in the present study total days of methamphetamine use was negatively correlated with cortical area, the less accumulated use observed in our sample might have placed our participants at less risk for accelerated, age-related decline. Taken together, the results from our study and prior work imply that very long-term methamphetamine use (perhaps \>10 years) places users at risk for accelerated, age-related brain tissue loss, but that early abstinence might mitigate this risk.

### 4.3.2. HIV status {#s0110}

Although there was no significant HIV diagnosis by age interaction for regional cortical area or volume, there were significant HIV by age interactions associated with regional thickness in eight ROIs. Across these ROIs, we observed a pattern in which HIV seropositive participants showed a more gradual decline in cortical thickness with older age than did HIV seronegative participants ([Fig. 2](#f0010){ref-type="fig"}). These results imply that the cortex is thinner among young HIV seropositive individuals compared to their seronegative age peers, and is an age-related replication of cortical thinning in other recently reported studies of HIV infection ([@bb0150]; [@bb0260]; [@bb0420]; [@bb0450]; [@bb0430]).

Our finding that nadir---but not current---CD4 count was inversely correlated with global cortical area and volume is consistent with prior working showing stronger associations of disease history factors (nadir CD4 and duration of infection) than current disease factors with overall cortical volume ([@bb0105]; [@bb0195]; [@bb0240]). Our findings contribute to the growing body of evidence that morphometric changes associated with HIV diagnosis might be due to brain injury that occurs after infection but before antiretroviral treatment begins. In a longitudinal study, the duration of untreated HIV infection was associated with cortical thinning in the frontal, temporal, and cingulate cortex in newly-infected individuals ([@bb0425]). Moreover, patients who underwent proton spectroscopy soon after HIV infection showed evidence of neuroinflammation in the basal ganglia and occipital gray matter which reversed after antiretroviral treatment ([@bb0415]). These results support the importance of beginning antiretroviral treatment as soon after HIV infection as possible in order to prevent neuroinflammation and neuronal damage. The average time between HIV infection and diagnosis is 5.6 years in the United States ([@bb0210]). Moreover, youthful age is one of the risk factors for poor treatment adherence ([@bb0380]; [@bb0280]). Together, delays in beginning ARV treatment and poor treatment adherence likely account for the lower intercept among HIV positive individuals when cortical thickness was regressed onto age.

Alternative factors could explain both the lower intercept and attenuated slope observed for cortical thickness in the HIV seropositive group. The observed cortical thinness associated with HIV status could have been present premorbidly. Demographic variables hypothesized to contribute to brain reserve, such as education and general intellectual functioning, have been associated with thinner cortex or with the trajectory of cortical change over time among HIV-negative individuals ([@bb0310]; [@bb0335]; [@bb0445]). However, in our study, there was no main effect of HIV status on education or premorbid verbal intelligence, which argues against the notion that any premorbid difference was related to cognitive reserve. It is possible that the attenuated slope observed in our HIV seropositive participants reflected an age-related, neuroprotective effect of HAART. In a recent study, treatment duration in recently-initiated patients was associated with small increases in cortical thickness in the right and temporal lobes ([@bb0425]). Yet, evidence is mounting that chronic anti-retroviral treatment potentiates neuronal damage rather than protecting neurons from aging, despite their acute benefits ([@bb0095]; [@bb0490]). Sorting out the favorable versus unfavorable effects of HAART on long-term brain health is a fertile topic for future HIV research.

### 4.3.3. Limitations {#s0115}

This study has a number of limitations. The cross-sectional design precludes drawing causal conclusions and is susceptible to cohort effects, such as differential morbidity that might have biased who survived to the older ages. Most of our older participants fell into the young-old range, limiting the conclusions we could draw about the effects of HIV infection and methamphetamine dependence in more advanced age groups. Worth noting are three recent longitudinal studies that have shown no differences in brain morphometry ([@bb0125]) or no difference in morphometric trajectory between HIV seropositive and control participants across a 2-year period of middle age ([@bb0110]; [@bb0430]). These findings suggest that the age-related trajectories we observed cross-sectionally may not reflect true patterns of individual-level change. Finally, the methamphetamine positive and negative groups were not matched on education -- potentially complicating the attribution of methamphetamine dependence as a cause of the cortical thinning we observed in the posterior cingulate gyrus. To address this potential limitation, we entered education into an analysis as a covariate and found that the posterior cingulate gyrus remained significantly thinner in the METH positive group, mitigating somewhat the interpretive concerns associated with the education mismatch.

5. Conclusion {#s0120}
=============

In summary, we generally found small statistical effects of HIV infection on regional cortical thickness or area with no effect surviving multiple statistical test correction. Mean cortical volume was significantly smaller among individuals living with HIV infection in the rostral middle frontal gyrus and in the inferior and superior parietal lobes. Methamphetamine dependence was associated with reduced regional thickness only in the posterior cingulate. Exploratory analyses of disorder-related variables revealed that lower CD4 nadir was associated with smaller global cortical area and volume, and total days of methamphetamine use was associated with smaller global cortical area.

We did not find robust evidence that methamphetamine status potentiates an adverse effect of HIV infection on cortical area, volume or thickness. In several cortical regions, we did observe interaction trends where methamphetamine dependence was associated with larger cortical area, but only in the HIV seropositive group. In general, however, the most robust effects of HIV infection and methamphetamine dependence on cortical structure appear to be additive.

Examining age-related changes in morphometry in relation to our clinical variables, we found that younger HIV seropositive individuals had thinner cortex compared to age peers, and the HIV seropositive group showed an attenuated age-related decline in cortical thickness. The apparent impact of HIV infection on cortical thickness at a young age coupled with the finding that lower CD4 nadir was associated with smaller cortical area highlights the need for initiating combined antiretroviral therapy as soon as possible after HIV diagnosis in order to prevent acute neural injury and its long-term consequences.
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[^1]: Note. Values in parentheses are standard deviations.

[^2]: All treated HIV patients but one were on highly active ART (antiretroviral therapy).

[^3]: HAND: Percent of group diagnosed with HIV Associated Neurocognitive Disorder.
